HM 15275
Alternative Names: HM-15275Latest Information Update: 08 Nov 2025
At a glance
- Originator Hanmi Pharmaceutical
- Class Heart failure therapies; Obesity therapies
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Obesity
- Preclinical Heart failure
Most Recent Events
- 31 Oct 2025 Hanmi Pharmaceutical Company plans a phase II trial for Obesity in USA (SC, Injection) (NCT07205900)
- 20 Jun 2025 Efficacy, safety and pharmacokinetic data from a phase I study in Obesity presented at 85th Annual Scientific Sessions of the American Diabetes Association (ADA 2025)
- 20 Jun 2025 Pharmacodynamics data from preclinical trials in Obesity presented at the 85th Annual Scientific Sessions of the American Diabetes Association (ADA-2025)